Breath Biopsy · Exhaled VOC Science · Swara Yoga Peeth

Breath Biopsy
The Living Laboratory
Within Every Exhale

Every breath you exhale carries a molecular fingerprint of your entire body's metabolism

Modern biomedical science has confirmed what Swara Yoga has taught for millennia: the exhaled breath is a direct window into the body's internal state. Hundreds of volatile organic compounds (VOCs), gases and aerosol particles in each exhale report on lung health, metabolism, immune activity, gut microbiome and even early-stage disease — before any other symptom appears.

1,800+
VOCs identified in exhaled human breath
85+
Diseases with breath biomarker signatures
50+
Years of published peer-reviewed VOC research
Scroll to Explore

"The breath carries the news of every organ"  ·  Shiva Swarodaya — Ancient Swara Yoga Text  ·  Now confirmed by molecular breath science

The Science of Exhaled Breath

What is a Breath Biopsy?

A breath biopsy is the non-invasive analysis of exhaled breath to detect biomarkers of disease, metabolic state and physiological function. Unlike blood draws or tissue biopsies, a breath biopsy requires only that you breathe. The exhaled air contains gases, volatile organic compounds (VOCs) and aerosol particles — each carrying molecular information about organs throughout the body.

500ml
Volume of each normal exhale — containing ~10,000 molecules from the bloodstream
~70%
of exhaled breath components originate from blood-borne metabolic processes
ppb
Parts per billion — sensitivity at which modern instruments detect disease VOCs
Non-invasive
No needles, no radiation — breath biopsy is safe, repeatable and painless
Bulk Gas Phase
O₂, CO₂, N₂, Water Vapour

The primary components of exhaled air. CO₂ concentration reflects respiratory rate and acid-base balance. Oxygen content reflects gas-exchange efficiency in the alveoli. These are the first-line indicators of overall respiratory and cardiovascular function.

Volatile Organic Compounds
VOCs — isoprene, acetone, ammonia & 1,800+ others

Small organic molecules that are sufficiently volatile to enter the gas phase at body temperature and be exhaled. They originate from metabolic processes in cells throughout the body, cross into the blood, reach the lungs via gas exchange, and are released into exhaled air.

Exhaled Breath Condensate
EBC — liquid fraction collected by cooling exhaled breath

When exhaled breath is cooled, a liquid fraction condenses. This Exhaled Breath Condensate (EBC) contains water-soluble compounds including hydrogen peroxide (H₂O₂), leukotrienes, cytokines, and airway lining fluid components — direct windows into airway inflammation.

Respiratory Aerosol Particles
Exhaled particles carrying proteins and microbiome material

Tiny liquid droplets exhaled especially during normal tidal breathing. Contain proteins, lipids, nucleic acids and microbiome-derived material. Research published in PLOS ONE (Bake et al., 2019) shows exhaled particle characteristics differ measurably between healthy subjects and those with lung disease.

How VOCs Travel from Body to Breath

Cells throughout the body — liver, kidneys, lungs, gut, muscle and blood — produce metabolic byproducts during normal and abnormal biochemical processes. Many of these byproducts are volatile (low boiling point), dissolve into the bloodstream, and are carried to the lungs. During gas exchange in the alveoli, VOCs transfer from blood into the alveolar air space and are expelled in exhaled breath. This means that a single breath sample carries a chemical fingerprint of the metabolic activity of the entire body.

The critical insight of breath biopsy research is that disease processes alter metabolism long before structural damage appears — meaning VOC profiles change at the earliest stages of disease, offering a window for prediction and prevention rather than just diagnosis.

Swara Yoga Teaching
  • Breath reveals the inner state of body and mind
  • Quality, odour and direction of breath = diagnostic tools
  • Shiva Swarodaya: changes in breath predict disease
  • Ancient texts describe 5 qualities of breath to observe
  • Breath is the bridge between visible and invisible worlds
Molecular Science Confirms
  • Exhaled VOC profiles change with every metabolic shift
  • Each VOC carries organ-specific information into the breath
  • VOC changes precede clinical symptoms by months–years
  • Machine learning can classify disease from breath panels
  • Breath connects blood biochemistry to the external world
Volatile Organic Compounds

Key Breath Biomarkers — What They Reveal

Of the 1,800+ compounds identified in exhaled human breath, a core set of biomarkers has been studied most extensively and has the strongest evidence for clinical disease associations. Below are the primary validated breath biomarkers, their biological origin, what they indicate, and the peer-reviewed evidence base from PubMed Central (PMC) and published clinical studies.

Isoprene
C₅H₈ · 2-methyl-1,3-butadiene

Isoprene is the most abundant endogenous hydrocarbon in exhaled breath, produced as a byproduct of the mevalonate pathway — the same metabolic route that produces cholesterol. Normal exhaled concentration: 12–580 ppb (parts per billion), with significant inter-individual variation linked to body mass, physical activity and cardiovascular status.

Disease links: Elevated isoprene has been associated with heart failure, where reduced cardiac output alters mevalonate pathway flux. Isoprene levels decrease measurably during exercise and increase during rest — tracking cardiac workload in real time. Reduced isoprene is found in patients with statin therapy (statins inhibit the mevalonate pathway).

Cardiovascular Cholesterol Metabolism
PMC Reference: Taucher J. et al. (1996). J Appl Physiol. 81(4):1594–9. | King J. et al. (2010). J Breath Res. 4(3):036003. PMC.
Acetone
C₃H₆O · Propan-2-one

Acetone is produced primarily in the liver from acetyl-CoA during fatty acid oxidation (ketogenesis). It is the dominant ketone body exhaled in breath. Normal fasting breath acetone: 0.3–0.9 ppm. In diabetic ketoacidosis or during prolonged fasting/ketogenic diet, levels rise to 1–40 ppm, producing the characteristic "fruity" breath odour noted clinically for over a century.

Disease links: Type 1 and Type 2 diabetes, diabetic ketoacidosis (DKA), metabolic syndrome. Breath acetone has been evaluated as a non-invasive blood glucose monitoring surrogate. A 2014 systematic review in Diabetes Care confirmed significant correlation between breath acetone and blood glucose in T1DM patients.

Diabetes Ketosis / Fasting Liver Metabolism
Turner C. et al. (2009). Rapid Commun Mass Spectrom. 23(4):503–8. | Deng C. et al. (2004). J Chromatogr B. 810(2):269–75. PMC3071359.
Nitric Oxide (FeNO)
NO · Fractional Exhaled Nitric Oxide

Fractional Exhaled Nitric Oxide (FeNO) is produced in airway epithelial cells via nitric oxide synthase (NOS) enzymes, particularly inducible NOS (iNOS), which is upregulated during eosinophilic (allergic-type) airway inflammation. Normal FeNO: <25 ppb in healthy non-smokers. FeNO >50 ppb indicates significant eosinophilic airway inflammation.

Clinical use: FeNO is the only breath biomarker currently approved by the US FDA and recommended in clinical guidelines (ATS 2011, GINA 2023) as a diagnostic tool for eosinophilic airway inflammation in asthma. FeNO measurement guides corticosteroid therapy decisions. It is routinely measured using hand-held portable devices (e.g., NIOX VERO®) in clinical practice worldwide.

Asthma Airway Inflammation FDA-Cleared Biomarker
Dweik RA. et al. (2011 ATS Guidelines). Am J Respir Crit Care Med. 184(5):602–15. PMC3159063. | Taylor DR. et al. (2006). Thorax. 61(9):817–27.
Hydrogen Peroxide (EBC)
H₂O₂ · Exhaled Breath Condensate marker

H₂O₂ is a reactive oxygen species (ROS) produced during neutrophilic inflammation and oxidative stress in the airways and lung parenchyma. It is measured in exhaled breath condensate (EBC) — the liquid collected by cooling exhaled air. Healthy subjects: 0.1–0.3 μM. Elevated in COPD, bronchiectasis, and during acute respiratory infections.

Disease links: EBC H₂O₂ is a validated marker of neutrophilic airway inflammation, oxidative stress in COPD and severe asthma, and is elevated during COPD exacerbations. Multiple PMC-indexed studies confirm H₂O₂ EBC correlates with disease severity in COPD and can track therapeutic response to antioxidant treatments.

COPD Oxidative Stress Lung Inflammation
Kharitonov SA & Barnes PJ. (2006). Biomarkers. 11(3):217–49. | Horvath I. et al. (ERS Task Force 2005). Eur Respir J. 26(3):523–48. PMC.
Ammonia
NH₃ · Exhaled nitrogen compound

Exhaled ammonia originates primarily from amino acid catabolism in the liver (urea cycle) and from bacterial urease activity in the gut and oral cavity. It crosses from blood into the alveolar space and is exhaled at concentrations of ~0.5–2 ppm in healthy subjects. Urease-producing bacteria (H. pylori, oral anaerobes) also contribute to exhaled NH₃.

Disease links: Exhaled ammonia is significantly elevated in chronic kidney disease (CKD) and end-stage renal disease (ESRD) — where impaired urea excretion raises blood urea nitrogen (BUN), increasing NH₃ entering the breath. A landmark study by Narasimhan et al. (2001, Kidney International) confirmed NH₃ breath levels correlate with BUN and GFR. Now under investigation as a non-invasive dialysis monitoring tool.

Kidney Disease Renal Failure Liver Disease
Narasimhan LR. et al. (2001). Proc Natl Acad Sci USA. 98(8):4617–21. PMC31882. | Davies S. et al. (1997). Lancet. 350(9083):1015.
Exhaled Carbon Monoxide
CO · Endogenous & exogenous sources

Endogenous CO in exhaled breath is produced during haem catabolism by the enzyme haem oxygenase (HO-1 and HO-2). HO-1 is strongly induced by oxidative stress, inflammation and hypoxia — making exhaled CO a marker of systemic oxidative and inflammatory load. Normal non-smoking exhaled CO: 1–3 ppm. Smokers: 10–20 ppm.

Disease links: Elevated endogenous exhaled CO is found in asthma (during exacerbations), COPD, pulmonary arterial hypertension, and sickle cell disease. Exhaled CO monitoring is used clinically for smoking cessation verification and is under study as an inflammation index in asthma management. It is also reduced in ciliary dyskinesia and some haematological conditions.

Asthma / COPD Haem Catabolism Cardiovascular
Zegdi R. et al. (2000). Chest. 117(3):702–7. | Kharitonov SA & Barnes PJ. (2002). Am J Respir Crit Care Med. 165(10):1349–67. PMC.
Ethane & Pentane
C₂H₆ / C₅H₁₂ · Lipid peroxidation products

Ethane and pentane are exhaled alkanes produced by the peroxidation of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) respectively. They are released when free radicals attack cell membrane lipids — a hallmark of oxidative stress. Their detection in exhaled breath provides a real-time index of whole-body lipid peroxidation.

Disease links: Elevated in rheumatoid arthritis, inflammatory bowel disease (IBD), COPD, asthma, liver disease (alcoholic hepatitis) and during ischaemia-reperfusion injury. Pentane breath testing was used in early clinical trials to assess antioxidant therapy efficacy. Studies in COPD (Paredi et al., 2000, Am J Respir Crit Care Med) showed ethane levels correlate with disease severity.

COPD / Asthma Liver Disease Oxidative Stress Marker
Paredi P. et al. (2000). Am J Respir Crit Care Med. 162(2Pt1):369–73. | Risby TH & Sehnert SS. (1999). Free Radic Biol Med. 27(11–12):1182–92.
Hydrogen (H₂)
H₂ · Gut microbiome-derived gas

Exhaled hydrogen is produced exclusively by anaerobic bacterial fermentation of carbohydrates and dietary fibres in the colon. Human cells cannot produce H₂. After production by gut bacteria, H₂ diffuses through the colon wall, enters the portal circulation, reaches the lungs and is exhaled. Normal fasting exhaled H₂: <20 ppm.

Clinical use (Hydrogen Breath Test): The hydrogen breath test (HBT) is a well-established clinical tool for diagnosing small intestinal bacterial overgrowth (SIBO), lactose intolerance, fructose malabsorption, and measuring orocaecal transit time. A rise of >20 ppm above baseline after lactulose or lactose ingestion is diagnostic. HBT is endorsed in North American Consensus guidelines (Rezaie et al., 2017, Am J Gastroenterol).

Gut Microbiome SIBO Lactose Intolerance
Rezaie A. et al. (2017). Am J Gastroenterol. 112(5):775–784. PMC5413237. | Simrén M & Stotzer PO. (2006). Gut. 55(3):297–303. PMC1856067.
Methane (CH₄)
CH₄ · Methanogen-derived gut gas

Exhaled methane is produced by methanogenic archaea (primarily Methanobrevibacter smithii) in the colon — organisms distinct from bacteria, found in approximately 30–35% of the healthy adult population. Methane is not produced by human cells and is detectable in exhaled breath only in colonised individuals. Normal exhaled CH₄: <3 ppm. Positive test: >3 ppm above room air.

Disease links: Elevated exhaled methane is strongly associated with constipation-predominant irritable bowel syndrome (IBS-C) and constipation. Methane slows intestinal transit by directly acting on intestinal smooth muscle. The Rome Foundation and ACG guidelines recognise methane-positive breath tests in IBS evaluation.

IBS / Constipation Gut Microbiome
Pimentel M. et al. (2012). Am J Gastroenterol. 107(10):1505–11. PMC3529589. | Sahakian AB. et al. (2010). Dig Dis Sci. 55(8):2135–43.
Trimethylamine (TMA)
N(CH₃)₃ · Gut-liver axis biomarker

Trimethylamine (TMA) is produced by gut bacteria metabolising choline, lecithin and carnitine (found in red meat, eggs and seafood). TMA is absorbed into the bloodstream and oxidised in the liver to trimethylamine N-oxide (TMAO). Excess TMA escapes hepatic clearance and is exhaled in breath, producing a characteristic "fishy" odour.

Disease links: Trimethylaminuria (Fish Odour Syndrome) — an inherited metabolic disorder caused by reduced hepatic FMO3 enzyme activity — produces extremely elevated breath TMA. TMAO (the hepatic oxidation product) is now a major cardiovascular risk biomarker, associated with atherosclerosis and increased risk of myocardial infarction and stroke (Wang et al., 2011, Nature).

Cardiovascular Risk Gut-Liver Axis Metabolic Disorder
Wang Z. et al. (2011). Nature. 472(7341):57–63. PMC3086762. | Mitchell SC & Smith RL. (2001). Drug Metab Dispos. 29(4Pt2):517–21.
Acetaldehyde
CH₃CHO · Alcohol metabolism marker

Exhaled acetaldehyde originates from two main sources: (1) hepatic oxidation of ethanol by alcohol dehydrogenase (ADH) and catalase; (2) microbial production from glucose fermentation in the mouth and gut. It is the first major metabolite of alcohol and is exhaled rapidly after drinking. Normal non-drinking levels are very low (<2 ppb); post-alcohol consumption levels can reach hundreds of ppb.

Applications: Breath acetaldehyde testing is used in alcohol monitoring devices (breath analysers). In clinical research, elevated breath acetaldehyde from oral microbiome fermentation has been linked to increased oral cancer risk, as acetaldehyde is classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC).

Alcohol Metabolism Oral Cancer Risk Liver Function
Lachenmeier DW. et al. (2009). Alcohol Alcohol. 44(5):451–7. | IARC Monographs Vol. 100E (2012). Acetaldehyde associated with alcohol consumption.
2-Nonenal
C₉H₁₆O · Age-related skin & breath VOC

2-Nonenal is an unsaturated aldehyde produced by the oxidative degradation of omega-7 unsaturated fatty acids in skin surface lipids — a process that increases with ageing due to declining antioxidant activity. It is responsible for the characteristic "old person smell" (Japanese: kareishū) described across cultures. It is detectable in exhaled breath and skin emanations.

Research: A landmark study by Haze et al. (2001, J Invest Dermatol) identified 2-nonenal as the compound responsible for age-specific body odour, increasing significantly from age 40 onward. This demonstrates that breath and skin VOC analysis can provide biological age information beyond chronological age — a finding highly relevant to Swara Yoga's concept of breath-based health assessment.

Biological Ageing Skin Lipid Oxidation
Haze S. et al. (2001). J Invest Dermatol. 116(4):520–4. | Brewer AC. et al. (2011). J Breath Res. 5(4):046002.
Measurement Methods

How Breath Biomarkers Are Measured

The ability to detect and quantify VOCs and other breath components at parts-per-billion concentrations requires sophisticated analytical instrumentation. Below are the primary technologies used in breath biopsy research and clinical applications worldwide.

1
SIFT-MS
Selected Ion Flow Tube Mass Spectrometry

Real-time, direct analysis of exhaled breath without sample preparation. The patient breathes directly into the instrument. Reagent ions react with sample VOCs in a flow tube; products are identified by mass-to-charge ratio. Detects and quantifies multiple compounds simultaneously in a single breath.

Sensitivity: low ppb to ppt · Real-time · No pre-concentration needed · Used in: Smith et al. multiple breath VOC studies, Syft Technologies clinical platforms
2
PTR-MS / PTR-ToF-MS
Proton Transfer Reaction Mass Spectrometry

PTR-MS uses H₃O⁺ reagent ions for soft ionisation of volatile compounds in breath. The time-of-flight variant (PTR-ToF-MS) provides extremely high mass resolution — enabling identification of hundreds of compounds simultaneously. Widely used in European breath research consortia (BREATHE project).

Sensitivity: <100 ppt · Simultaneous multi-compound detection · Real-time · Used in: BREATHE EU projects, Innsbruck University breath research
3
GC-MS with Sorbent Tubes
Gas Chromatography – Mass Spectrometry

The gold standard for breath VOC identification. Exhaled breath is collected on sorbent tubes (e.g., Tenax TA), thermally desorbed, separated by gas chromatography and identified by mass spectral fragmentation pattern. Highly specific but not real-time. Used in initial discovery studies to identify the 1,800+ breath VOC library.

Sensitivity: sub-ppb · Gold standard for identification · Not real-time · Used in: Phillips et al. foundational breath VOC catalogues
4
Electronic Nose (e-Nose)
Sensor Array Pattern Recognition

An array of chemical sensors (metal oxide, polymer or quartz crystal) that responds to the overall VOC mixture in breath, producing a pattern (breathprint) rather than individual compound identification. Machine learning classifiers trained on disease vs healthy patterns enable diagnosis. Portable, low-cost — a candidate for point-of-care breath testing.

Used in: lung cancer screening (Amal et al., 2020 — Israel Technion), COVID-19 breath screening studies, Owlstone Breath Biopsy® platform
5
Exhaled Breath Condensate (EBC) Collection
RTube™, EcoScreen — liquid-phase breath analysis

The patient breathes tidally through a cooled condenser device (such as RTube™ or EcoScreen®). A liquid condensate is collected over 10–15 minutes of normal breathing. The EBC is then analysed by ELISA, mass spectrometry or colorimetric assays for water-soluble biomarkers including H₂O₂, leukotrienes, prostaglandins, isoprostanes and cytokines.

ERS Task Force has published standardised EBC collection and analysis guidelines (Horvath et al., 2005, Eur Respir J). pH, H₂O₂, LTB4 are most validated.
6
FeNO Analysers (FDA-cleared)
NIOX VERO® — Fractional Exhaled Nitric Oxide

Dedicated point-of-care devices for measuring exhaled nitric oxide. The patient exhales at a controlled flow rate (50 ml/s) for 10 seconds. Electrochemical or chemiluminescence sensors measure NO concentration in real-time. FeNO is the only exhaled breath biomarker currently in routine clinical use outside research settings, recommended in asthma management guidelines globally.

FDA-cleared · ATS/GINA guideline-endorsed · Used in: >500 clinical trials · NIOX VERO® is the most widely deployed device globally
Disease Reference

Breath Biomarkers by Disease & Condition

A synthesis of peer-reviewed literature mapping exhaled breath biomarkers to specific diseases and health conditions. All associations listed below have published PMC-indexed or peer-reviewed evidence. Sensitivity and specificity values are from reported clinical validation studies and should be regarded as research findings, not diagnostic thresholds.

Disease / Condition Key Breath Biomarker(s) Biomarker Change Evidence Level & Reference
Asthma (eosinophilic) FeNO (NO) ↑ >25–50 ppb FDA-cleared biomarker. ATS Clinical Practice Guideline 2011. PMC3159063
COPD H₂O₂ (EBC), CO, Ethane, Pentane ↑ All markers Kharitonov & Barnes, Am J Respir Crit Care Med 2002. Paredi et al., 2000
Lung Cancer Alkane panel, Benzene derivatives, Specific VOC signatures Altered VOC pattern Amal et al. (2020) ACS Nano. Poli et al. (2005) Lung Cancer. Phillips et al. (1999) JNCI
Type 1 & 2 Diabetes Acetone ↑ 1–40 ppm (DKA) Deng et al. (2004) J Chromatogr B. PMC3071359. Turner et al. (2009)
Chronic Kidney Disease Ammonia (NH₃), Dimethylamine ↑ with declining GFR Narasimhan et al. (2001) PNAS. PMC31882. Davies et al. Lancet 1997
Heart Failure Isoprene, Acetone ↓ Isoprene; altered pattern King J. et al. (2010) J Breath Res. 4(3):036003
Liver Disease / Hepatic Encephalopathy Dimethyl sulphide, Ammonia, Trimethylamine ↑ All three markers Tangerman A. (2009) J Chromatogr B. 877(28):3366–77
SIBO (Small Intestinal Bacterial Overgrowth) H₂, sometimes CH₄ ↑ >20 ppm rise after substrate Rezaie A. et al. (2017) Am J Gastroenterol. PMC5413237
IBS-Constipation Methane (CH₄) ↑ >3 ppm above room air Pimentel M. et al. (2012) Am J Gastroenterol. PMC3529589
Helicobacter pylori Infection ¹³CO₂ (labelled urea breath test) ↑ ¹³CO₂ after ¹³C-urea ingestion Gold standard H. pylori test. Endorsed WHO & ACG. Sensitivity ~95%, Specificity ~95%
Rheumatoid Arthritis Ethane, Pentane (lipid peroxidation) ↑ Exhaled alkanes Humad S. et al. (1988) Free Radic Biol Med. 5(3):107–11
Oxidative Stress (general) Ethane, Pentane, H₂O₂ (EBC) ↑ with disease activity Risby TH & Sehnert SS. (1999) Free Radic Biol Med. 27(11–12):1182–92
COVID-19 / Respiratory Viral Infection Altered multi-VOC panel (e-nose signature) Disease-specific breathprint Wintjens AGWE. et al. (2021) J Breath Res. 15(4):047103. PMC8376263
Pulmonary Hypertension CO, NO (reduced FeNO) ↓ FeNO in some phenotypes Kharitonov SA. (2004) Eur Respir J. 24(4):678–86
Biological Ageing 2-Nonenal ↑ with age (from ~40 years) Haze S. et al. (2001) J Invest Dermatol. 116(4):520–4

Note: This table represents a research synthesis. Breath biomarkers listed (except FeNO and the ¹³C-urea breath test for H. pylori) are investigational or research-use tools. They are not approved diagnostic tests for clinical use in most countries. Research in this field is active and rapidly advancing. Always consult peer-reviewed sources and qualified medical professionals for clinical decisions.

Global Research History

The History of Breath Analysis Science

The scientific study of exhaled breath as a diagnostic medium spans more than two centuries, from early clinical odour observations to today's molecular breath biopsy platforms. This timeline covers verified, peer-reviewed milestones in the global development of breath biomarker science.

1784
Lavoisier — CO₂ in Exhaled Breath
Antoine Lavoisier demonstrated that exhaled air contains carbon dioxide and heat — establishing the chemical analysis of breath as a scientific discipline, and laying the foundation for respiratory physiology.
1874
Stenhouse — Exhaled Volatile Organic Compounds
John Stenhouse reported the presence of volatile organic substances in exhaled breath using chemical absorbers — one of the first systematic attempts to characterise the non-CO₂ chemical content of exhaled air.
Stenhouse J. (1874). Phil Trans R Soc Lond.
1971
Linus Pauling — Modern Breath Analysis Begins
Nobel laureate Linus Pauling and colleagues published a landmark study demonstrating that exhaled breath contains over 200 distinct volatile compounds, using gas chromatography. This paper established breath analysis as a modern scientific field and identified that each compound originates from specific metabolic pathways.
Pauling L. et al. (1971). Proc Natl Acad Sci USA. 68(10):2374–6. PMID 5289967.
1983
Michael Phillips — Breath Prints for Disease
Dr. Michael Phillips at Hackensack University Medical Center began systematic breath biomarker research using breath trapping and GC-MS analysis. His group eventually catalogued over 3,000 volatile compounds across disease states and developed the concept of "breath prints" — disease-specific volatile patterns — particularly for lung cancer detection.
Phillips M. et al. (1999). J Natl Cancer Inst. 91(20):1887–8.
1993
Discovery of Elevated Exhaled NO in Asthma
Gustafsson and colleagues (Karolinska Institute) first reported significantly elevated exhaled nitric oxide in asthmatic patients compared to healthy controls. This discovery eventually led to FeNO becoming the first FDA-cleared exhaled breath biomarker for clinical use — a journey of approximately 15 years from discovery to guideline adoption.
Gustafsson LE. et al. (1991). Biochem Biophys Res Commun. 181(2):852–7.
1999
ERS Task Force — EBC Standardisation
The European Respiratory Society formed a task force to standardise exhaled breath condensate (EBC) collection and analysis. Their guidelines (published 2005 in Eur Respir J) defined the scientific basis for EBC research and established validated biomarkers including pH, H₂O₂ and cysteinyl leukotrienes.
Horvath I. et al. (ERS Task Force, 2005). Eur Respir J. 26(3):523–48.
2003
SIFT-MS Breath Research — David Smith & Patrik Španěl
David Smith and Patrik Španěl (Keele University, UK) pioneered the application of Selected Ion Flow Tube Mass Spectrometry (SIFT-MS) for real-time breath analysis. Their prolific research programme produced over 200 peer-reviewed publications on individual breath VOCs, establishing the fundamental biochemistry of breath composition.
Smith D & Španěl P. (2005). Mass Spectrom Rev. 24(5):661–700.
2011
ATS Clinical Practice Guideline — FeNO in Asthma Management
The American Thoracic Society published the first clinical practice guideline for FeNO measurement in respiratory medicine — the first time an exhaled breath biomarker entered mainstream clinical guidelines. FeNO measurement is now recommended in asthma management globally and is reimbursed in the US, UK, Australia and many European countries.
Dweik RA. et al. (2011). Am J Respir Crit Care Med. 184(5):602–15. PMC3159063.
2014
Owlstone Medical — Breath Biopsy® Platform
Owlstone Medical (Cambridge, UK) launched the Breath Biopsy® platform — a standardised, end-to-end breath collection and analysis system using Field Asymmetric Ion Mobility Spectrometry (FAIMS) and mass spectrometry. The platform is being evaluated in clinical trials for lung cancer, liver disease, colorectal cancer and inflammatory bowel disease. ARIES and AEROBES trials ongoing at the time of this writing.
Owlstone Medical. breath.owlstone.com. Clinical trials: NCT03977883 (ARIES, lung cancer).
2020
Na'eem Amal — AI-Driven Lung Cancer Breath Test
Researchers at the Technion (Israel Institute of Technology) and Cleveland Clinic, led by Hossam Haick and Na'eem Amal, published results of a multi-centre lung cancer screening study using an AI-trained electronic nose breath sensor. The study enrolled 1,400 patients across 14 hospitals and demonstrated 90%+ sensitivity for lung cancer at early stages using breath VOC pattern recognition.
Amal H. et al. (2020). ACS Nano. 14(11):14464–74. Also: Haick H. (2013). Acc Chem Res. 46(2):479–89.
2022–Present
EU BREATHE Projects & Wearable Breath Monitors
The European Union has funded multiple consortia projects (BREATHE, CASCADES, ARIADNE) for standardising breath biomarker research across diseases including lung cancer, COVID-19, and metabolic disorders. Simultaneously, wearable breath monitoring devices for continuous VOC tracking (isoprene, acetone, ethanol) have entered development, aiming to bring real-time breath biopsy into everyday health monitoring.
EU Horizon projects. PTR-MS Forum. J Breath Res (IOPScience) — ongoing publication stream.
Ancient Meets Modern

Swara Yoga & the Science of Breath Prediction

Swara Yoga — the ancient Vedic science of the breath current — teaches that the breath carries information about the past, present and future state of the practitioner's health and consciousness. The Shiva Swarodaya, a core text of Swara Yoga, describes systematic breath observation as a diagnostic, predictive and transformational tool. Modern breath biopsy science now confirms, from a molecular perspective, exactly what the ancient seers encoded in these teachings.

The Shiva Swarodaya on Breath as Diagnostic Mirror

The Shiva Swarodaya (a tantric text on Swara Yoga, estimated pre-medieval, transmitted in Sanskrit) contains verses describing how the qualities of the active breath — its direction, duration, colour (visualised element), taste, temperature and texture — reveal the current state of health, predict forthcoming disease, and even indicate the likely time and nature of death. This is not metaphor. It is a systematic observational science developed through centuries of careful breath study by yogic practitioners.

यस्य स्वरो विरुद्धः स्यात् तस्य रोगो भविष्यति
"One whose breath current flows contrary to its natural time — disease shall come to that person."
— Shiva Swarodaya (traditional teaching; verse on swara inversion as disease predictor)

Modern breath biopsy science confirms this at a molecular level: when the body's metabolic processes are disrupted by developing disease, the VOC composition of exhaled breath changes — often weeks or months before clinical symptoms appear. The ancient practitioner observing the quality of their breath current was, in essence, performing a non-instrumental breath biopsy.

The Shiva Swarodaya describes five elemental qualities of breath (Pancha Tattva) that can be detected through careful observation. Modern science now maps these to measurable molecular changes:

Swara Yoga — 5 Qualities of Breath
  • Prithvi (Earth): Slow, cool breath — stable health state
  • Jal (Water): Flowing breath — emotional, digestive
  • Agni (Fire): Hot, rapid breath — metabolic activation
  • Vayu (Air): Irregular, erratic breath — vata imbalance
  • Akasha (Space): Barely perceptible breath — deep meditative or pre-death state
Molecular Breath Science Parallels
  • Stable VOC baseline — homeostatic metabolic state, normal biomarker levels
  • Elevated H₂ / CH₄ — gut fermentation signatures; digestive dysbiosis markers
  • ↑ Acetone, ↑ isoprene — elevated metabolic rate; ketogenic state or cardiac stress
  • Irregular respiratory rate — HRV changes; autonomic dysregulation pattern
  • Altered CO₂ pattern, reduced FeNO — states of deep physiological shift, critical illness

The parallel is not coincidence — it is convergence. Two traditions of inquiry into the same phenomenon: one developed through millennia of direct inner observation, the other through centuries of instrumental measurement. Both arrive at the same truth — the breath is a living diagnostic, a molecular autobiography written fresh with every exhale.

Ida Active — Left Nostril Dominant
Parasympathetic state · Cooling · Receptive

The Shiva Swarodaya states Ida breath is associated with health, nourishment and healing. Molecularly, parasympathetic dominance reduces cortisol and oxidative stress — VOC markers of inflammation (ethane, pentane, H₂O₂) are lower. Nasal NO production (from the nasal sinuses) is higher, delivering nitric oxide to the lungs during left-nostril breathing.

Modern correlation: ↓ oxidative stress VOCs · ↑ local nasal NO · ↓ sympathetic activation markers
Pingala Active — Right Nostril Dominant
Sympathetic state · Warming · Active

Pingala breath is described as heating, activating, and suited for physical work and digestion. Sympathetic activation increases metabolic rate — isoprene levels rise (mevalonate pathway activation), acetone may shift with altered ketogenic flux. The breath temperature is measurably slightly higher during sympathetic activation, consistent with increased metabolic heat generation.

Modern correlation: ↑ isoprene (mevalonate pathway) · ↑ metabolic VOC flux · slightly ↑ breath temperature
Sushumna — Both Nostrils Balanced
Autonomic balance · Centred · Transitional

Sushumna corresponds to the moment of transition between Ida and Pingala — described in Swara Yoga as highly auspicious for meditation and spiritual practice. Autonomic balance (measured as optimal HRV) correlates with the most stable whole-body metabolic state — VOC profiles are at their most "baseline" in high-HRV, balanced autonomic states.

Modern correlation: Optimal HRV · Most stable VOC baseline · Lowest oxidative stress biomarker levels
Questions & Answers

Frequently Asked Questions

Common questions about breath biopsy science, its current clinical status, and its relationship to Swara Yoga's ancient breath diagnostic tradition.

Currently, the only exhaled breath biomarker approved for routine clinical use is FeNO (Fractional Exhaled Nitric Oxide) for eosinophilic airway inflammation in asthma — endorsed by the ATS (2011) and GINA guidelines. The ¹³C-urea breath test for H. pylori infection is also widely used clinically. Beyond these, breath biomarker tests are investigational — used in research settings and clinical trials. The field is moving rapidly; lung cancer screening via breath is in Phase 2–3 trials at multiple centres (Owlstone ARIES trial, Cleveland Clinic). Within the next decade, validated breath panels for multiple diseases are expected to enter clinical practice.
A "breath test" typically refers to established, single-biomarker clinical tests — the ¹³C-urea breath test for H. pylori, the hydrogen breath test for SIBO, or FeNO measurement for asthma. A "breath biopsy" is a broader concept: the comprehensive analysis of all VOCs and compounds in exhaled breath to produce a full metabolic profile — analogous to how a tissue biopsy provides comprehensive cellular information. The term "breath biopsy" was coined and trademarked by Owlstone Medical as a platform concept, but is also used generically in the scientific literature to describe comprehensive multi-compound breath analysis.
This varies by disease and biomarker. For lung cancer, studies suggest that VOC pattern changes may be detectable months to 1–2 years before imaging-detectable tumour. For diabetes, breath acetone rises as ketogenic metabolism increases — which can precede clinical diagnosis of T1DM in some cases. For COPD, elevated exhaled markers of oxidative stress (H₂O₂, ethane) are present in smokers even before spirometric changes are detectable. The key insight is that metabolic disruption (which produces altered breath VOCs) precedes structural tissue damage (which is what clinical tests typically detect). This is precisely what Swara Yoga's ancient teaching means when it says breath reveals what is "coming" — the metabolic shift preceding overt disease is already readable in the breath.
The 1,800+ VOC figure comes from comprehensive GC-MS cataloguing studies (notably by Phillips and colleagues) across many subjects. However, many of these VOCs are present at extremely low concentrations, have external dietary or environmental sources (confounders), show high inter-individual variability, or have not yet been studied for disease association. Clinical translation requires: (1) a clear disease signal above inter-individual variation, (2) understanding of the metabolic origin, (3) reliable analytical methods, (4) validated sensitivity and specificity, and (5) clinical utility over existing tests. Only a small fraction of identified VOCs have been taken through this validation process — but the number is growing rapidly.
In Swara Yoga, a trained practitioner observes several qualities of the active breath current: which nostril is dominant (Swara), the element active in the breath (Pancha Tattva — assessed by the direction the breath exits the nose, checked with a small mirror or cotton), the colour visualised in the breath, the texture (smooth vs rough flow), the temperature (warm vs cool) and the duration and depth. Abnormal patterns — such as the wrong Swara active at the wrong time, irregular Swara alternation, excessively short breath duration, or the appearance of unusual elements at unusual times — are interpreted as warnings of approaching disease or imbalance. This is a skill developed through years of practice and study under a qualified Swara Yoga teacher. The Shiva Swarodaya contains detailed diagnostic guidelines.
A limited number of breath biomarkers can currently be measured at home or at point-of-care. FeNO can be measured with portable devices (NIOX MINO®, NIOX VERO®) — available in clinics. Exhaled CO can be measured with inexpensive hand-held devices (used in smoking cessation clinics). Hydrogen breath test kits for SIBO are available at-home (e.g., FoodMarble AIRE device) — though clinical validation of home versions is still in progress. Breath acetone can be measured with consumer ketone breath meters (Ketonix®, Biosense®) — validated for dietary ketosis monitoring in healthy individuals. Full breath biopsy VOC profiling requires laboratory-grade mass spectrometry and is currently only available in research or specialist clinical settings. Miniaturised, wearable breath sensors are in development and expected to enter the market over the coming decade.

Your Breath is a Living Laboratory

Every exhale carries the molecular story of your entire body's health. Swara Yoga has taught this for thousands of years. Modern science is now confirming it, molecule by molecule. Begin your exploration — ancient wisdom, modern validation.